We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $6 · 2 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Kezar Life Sciences (KZR) Holds Steady at $7.29 – Key Levels in Focus - Day Trade Opportunities - thelegaladvocate.com
Kezar Life Sciences (KZR) Holds Steady at $7.29 – Key Levels in Focus - Day Trade Opportunities thelegaladvocate.com
Kezar Life Sciences (KZR) Holds Steady at $7.29 – Key Levels in Focus - IPO Entry Watch - thelegaladvocate.com
Kezar Life Sciences (KZR) Holds Steady at $7.29 – Key Levels in Focus - IPO Entry Watch thelegaladvocate.com
Kezar Life Sciences Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Reports No Revenue - newsline.com
Kezar Life Sciences Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Reports No Revenue newsline.com
Baselake files Schedule 13G/A reporting 0 shares in Kezar Life Sciences (KZR) - Stock Titan
Baselake files Schedule 13G/A reporting 0 shares in Kezar Life Sciences (KZR) Stock Titan
Kezar Life Sciences Inc Financial Disclosures & Filings - TradingView
Kezar Life Sciences Inc Financial Disclosures & Filings TradingView
[15-12G] Kezar Life Sciences, Inc. SEC Filing - Stock Titan
[15-12G] Kezar Life Sciences, Inc. SEC Filing Stock Titan
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 12. | After market close (AMC) | $-0.91 | — | — | $0 | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2025. 10. 18. | Jefferies | — | Downgrade | Buy → Hold | — | Jefferies: Buy → Hold |
| 2025. 10. 17. | William Blair | — | Downgrade | Outperform → Market Perform | — | William Blair: Outperform → Market Perform |
| 2025. 10. 17. | Wells Fargo | — | Maintain | Equal-Weight → Equal-Weight | — | Wells Fargo: Equal-Weight |
| 2025. 07. 16. | HC Wainwright & Co. | — | Maintain | Neutral → Neutral | — | HC Wainwright & Co.: Neutral |
| 2024. 12. 19. | Wells Fargo | — | Maintain | Equal-Weight → Equal-Weight | — | Wells Fargo: Equal-Weight |
| 2024. 12. 02. | HC Wainwright & Co. | — | Maintain | Neutral → Neutral | — | HC Wainwright & Co.: Neutral |
Price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 11,312 | $71.15M | 0.00% | — | New position |